Evidence map›Paper›PMID 39716914›Full record

ArticleAmerican journal of physiology. Renal physiology2025

Glycerol-3-phosphate contributes to the increase in FGF23 production in chronic kidney disease.

Petra Simic, Han Xie, Qian Zhang, Wen Zhou, Rohan Cherukuru, Michael A Adams, Mandy E Turner, Eugene P Rhee

Abstract read
In one paragraph

Article in American journal of physiology. Renal physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. FGF23 - A hormone produced by bone and has many faces.Reviews in endocrine & metabolic disorders · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Lysophosphatidic Acid Synergizes With 1,25-Dihydroxyvitamin D to Promote Fibroblast Growth Factor-23 Synthesis via MAPK Signaling and Induction of the IL12A Gene.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Petra SimicNephrology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States.
Han XieNephrology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States.
Qian ZhangNephrology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States.
Wen ZhouNephrology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States.
Rohan CherukuruNephrology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States.ORCID 0009-0002-2866-0855
Michael A AdamsDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.
Mandy E TurnerDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.
Eugene P RheeNephrology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States.ORCID 0000-0002-4804-7583

Funding

Translational Imaging and Phenotyping CoreP30AR075042 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI Marie Demay · 2019 to 2026
$7.4M
Kidney Glycolysis as the Mammalian Phosphate SensorR01DK130291 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI RHEE, EUGENE P. · 2022 to 2025
$1.9M
Lysophosphatidic acid (LPA) is a novel FGF23 regulator in acute kidney injury.K08DK124568 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI SIMIC, PETRA · 2020 to 2024
$866k
HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) K08DK124568HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R01DK130291NIAMS NIH HHS P30 AR075042NIDDK NIH HHS K08 DK124568NIDDK NIH HHS R01 DK130291
6 · The paper itself

Abstract

Why fibroblast growth factor 23 (FGF23) levels increase markedly in chronic kidney disease (CKD) is unknown. Recently, we found that phosphate stimulates renal production of glycerol-3-phosphate (G-3-P), which circulates to the bone to trigger FGF23 production. To assess the impact of G-3-P on FGF23 production in CKD, we compared the effect of adenine-induced CKD in mice deficient in glycerol-3-phosphate dehydrogenase 1 (Gpd1), an enzyme that synthesizes G-3-P, along with wild-type littermates. We found that an adenine diet causes a similar degree of renal insufficiency across genotypes and that adenine-induced CKD increases blood G-3-P and FGF23 levels in wild-type mice. Furthermore, we found that the increases in both G-3-P and FGF23 are significantly attenuated, but not fully abrogated, in

Indexed as

Fibroblast Growth FactorsGlycerophosphatesKidneyRenal Insufficiency, ChronicAdenineAnimalsDisease Models, AnimalFibroblast Growth Factor-23Glycerolphosphate DehydrogenaseMaleMiceMice, Inbred C57BLMice, KnockoutPhosphatesRatsRats, Sprague-DawleyAdeninealpha-glycerophosphoric acidFgf23 protein, mouseFgf23 protein, ratFibroblast Growth Factor-23Fibroblast Growth FactorsGlycerolphosphate DehydrogenaseGlycerophosphatesPhosphatesCKDFGF23glycerol-3-phosphateglycerol-3-phosphate dehydrogenase 1mineral metabolism

Identifiers

PMID39716914
PMCPMC12167463

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.